Gut–Brain Signaling in Parkinson’s Disease: A Narrative Review
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27083531 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Karolina Ratajczyk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Karol Jonscher's Municipal Medical Center, Milionowa 14, 93-113 Lodz, Poland. Hauptthemen laut MEDLINE: Parkinson Disease, Brain, Gastrointestinal Microbiome, Signal Transduction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 266 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz.
Abstract (Originalsprache)
The formulation of the gut–brain–microbiota axis (GBA) theory has led to new research directions that have expanded our understanding of the pathogenesis, phenotypic variability, and clinical course of Parkinson’s disease (PD). Models of PD pathogenesis, based on the Braak hypothesis, suggest a subtype of the disease in which pathological changes begin in the gut many years before the onset of brain pathology and the manifestation of motor symptoms. Gut microbiota may influence nervous system function along the GBA by influencing intestinal permeability, chronic inflammation, and α-synuclein aggregation. Accumulating evidence suggests that the gut microbiota may also regulate the synthesis and metabolism of neurotransmitters, including dopamine (DA), serotonin (5-HT), acetylcholine (ACh) and γ-aminobutyric acid (GABA), both in the gut and brain, and indirectly stimulate central nervous system activity via the vagus nerve, which receives signals from the enteric nervous system. Research on the effects of microbiota on GBA has paved the way for the identification of novel treatment strategies, including probiotics, prebiotics, synbiotics, postbiotics, antibiotics, and fecal microbiota transplantation (FMT), aimed at not only symptomatic but also disease-modifying treatment of PD. In this article, we propose a novel approach to GBA as a link between gut microbiota and gut and brain neurotransmitter metabolism in PD. We review the latest research on the gut epithelial barrier. We analyze and summarize the potential of therapeutic interventions targeting gut microbiota and their impact on neurotransmitter regulation in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Karol Jonscher's Municipal Medical Center, Milionowa 14, 93-113 Lodz, Poland.
- Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.
- Department of Extrapyramidal Diseases, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland.
- Department of Neurology, Central University Hospital, Pomorska 251, 92-213 Lodz, Poland.
ORCID-Profile: Jakub Fichna, Agata Gajos
Förderung
- Medical University of Lodz
Zitieren
APA
Ratajczyk, K., Kaczorowska, E., Wyka, K., Tarasiuk-Zawadzka, A., Fichna, J., & Gajos, A. (2026). Gut–Brain Signaling in Parkinson’s Disease: A Narrative Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27083531
Vancouver
Ratajczyk K, Kaczorowska E, Wyka K, Tarasiuk-Zawadzka A, Fichna J, Gajos A. Gut–Brain Signaling in Parkinson’s Disease: A Narrative Review. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27083531
BibTeX
@article{Ratajczyk2026,
author = {Ratajczyk, Karolina and Kaczorowska, Emilia and Wyka, Karolina and Tarasiuk-Zawadzka, Aleksandra and Fichna, Jakub and Gajos, Agata},
title = {Gut–Brain Signaling in Parkinson’s Disease: A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27083531}
}
EUVIMED